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SUMMARY – Ulcerative colitis (UC) is a multifactorial disease of unknown precise etiology and 
immunopathogenesis. Peripheral blood granulocytes and monocytes/macrophages are the major 
sources of cytokines, which regulate inflammation. Leukocytapheresis (LCAP) is a method where 
blood is processed by apheresis system that removes lymphocytes and plasma before being returned to 
the body. We report the first case in Croatia where we used LCAP in the treatment of a patient with 
severe steroid-dependent UC. After 12 LCAP procedures, good clinical response was obtained and 
there were no significant adverse side effects noticed. The patient remained in clinical remission over 
two years in which he underwent regular follow ups at outpatient clinic. Over a 10-year follow-up 
period after LCAP, the patient had only occasional clinical symptoms of disease activity. The clinical 
course was complicated with the development of metastatic colorectal carcinoma, which points to the 
importance of regular disease monitoring rather than the increased risk of malignant disease after 
LCAP. Patients with UC are a demanding group of patients that warrant the search for novel treat-
ment strategies other than conventional pharmacological therapies. Although LCAP is still not a 
common treatment modality in our daily practice, data from recent studies suggest it to be an effective 
and safe procedure in the management of active UC patients.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory 
condition characterized by continuous mucosal in-
flammation, which is affecting the rectum and to a 
variable extent the colon. The disease course is relaps-
ing and remitting. Although the etiology and patho-
genesis remain uncertain, results of the studies suggest 
that atypical immune response to an environmental 
trigger in a genetically predisposed person could be re-
lated to the development of UC1. Medications used in 
the treatment of UC include anti-inflammatory drugs, 
steroids, immunosuppressive drugs and biological 
agents. These agents are used to induce and maintain 
remission and can have many side effects. Leukocy-
tapheresis (LCAP), a method that removes leukocytes 
from the circulatory system, is a non-pharmacological 
therapeutic approach for active UC. The mechanism of 
action consists of removal of the cell population in-
volved in bowel inflammation from peripheral blood, 
where circulating cytokines and specific inflammatory 
cells can be removed from blood by the use of specific 
filters2. Activated peripheral blood granulocytes are 
the source of many inflammatory cytokines, which are 
thought to be involved in the pathogenesis of UC. 
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 Activated peripheral granulocytes infiltrate the colonic 
mucosa where they interact with lymphocytes and ini-
tiate disease activity and relapse3-5. Bearing in mind 
those processes, it is thought that LCAP has the po-
tential to reduce inflammation, and possibly lead to 
reduction of steroid use in the management of patients 
with UC.
Different apheresis techniques have different ad-
sorption capacities and remove different types of leu-
kocytes. There are two most common techniques that 
involve removal of specific cells from the blood, using 
special filter of nonwoven polyester fibers (Cellsorba, 
Asahi Kasei Medical Company, Tokyo, Japan) or col-
umn containing cellulose acetate beds (Adacolumn, 
Jimro, Takasaki, Japan)6. Blood is drawn via a venous 
catheter, passed through the system where leukocyte 
adhere, and thereafter returned into the circulatory 
system. There are several recently published studies 
that showed LCAP to be a safe and effective therapeu-
tic option for active UC2,7. We present a case of a pa-
tient with severe UC and refractory anemia who was, 
for the first time in Croatia, treated with LCAP.
Methods
Leukocytapheresis serves for removal of plasma 
and mononuclear cells from the blood. We used the 
COBE Spectra apheresis system (Software Version 
6.1; Terumo BCT, Lakewood, USA) according to the 
COBE Spectra therapeutic apheresis guide protocol. 
For anticoagulation, citrate dextrose solution-A 
(ACD-A) was used. The blood flow was 47 mL/min. 
During each LCAP cycle, a total of 7502±1047 mL 
blood (1.5 x total blood volume) was processed and 
627.8±87.2 mL of ACD-A was used. The mean num-
ber of lymphocytes removed was 2.02±0.76x109, and a 
total of 2100±636 mL plasma was removed, which was 
50%-55% of the patient’s total plasma volume. Re-
moved plasma was replaced with 5% albumin in saline.
Case Report
A 27-year-old male patient was admitted to the 
Zagreb University Hospital Centre in April 2007 due 
to UC relapse and severe secondary anemia. Initially, 
UC was diagnosed in 2005 at the Split University 
Hospital Centre. Therapy with mesalazine was started 
and positive clinical response was achieved. In October 
2005, the patient was admitted to the hospital due to 
severe relapse of ulcerative pancolitis, therefore ste-
roids were introduced in therapy. Subsequently, aza-
thioprine at a dose of 2 mg/kg/day was started and the 
dose of steroid was gradually reduced. In November 
2006, the patient presented with maculopapulous rash 
in axillary region, groin and trunk. Dermatologists 
suggested these lesions to be side effects of steroids. In 
February 2007, the patient was referred to the Outpa-
tient Clinic for Inflammatory Bowel Diseases, Zagreb 
University Hospital Centre. Therapy with mesalazine 
4x1 g, azathioprine 2 mg/kg/day and gradual reduc-
tion of steroid dose was recommended. Upon steroid 
reduction, the patient’s clinical symptoms worsened 
again and he was hospitalized in March 2007 at De-
partment of Gastroenterology and Hepatology, Za-
greb University Hospital Centre. Conservative mea-
sures of treatment led to short-term clinical improve-
ment, but already in April 2007, the patient was ad-
mitted to our Department due to relapse of the disease 
and severe secondary anemia. The patient was admit-
ted to the hospital in extremely poor general condi-
tion, with tachycardia, up to 10 bloody watery stools 
per day, abdominal pain, and a history of weight loss of 
about 15 kg in the past year. Laboratory analysis re-
vealed increased inflammatory markers (erythrocyte 
sedimentation rate 150 mm/h, C-reactive protein 68 
mg/L) and severe anemia (E 1.81x1012, Hb 51 g/L, 
MCV 90.6 fl, MCH 29.1 pg). Intra-abdominal ab-
scess collection and gastrointestinal infection were ex-
cluded by initial examinations, while native rectosig-
moidoscopy showed entirely hyperemic and friable 
rectal mucosa, ulcerations covered with fibrin, sponta-
neous bleeding and pseudopolyps. Mayo Score was 10 
(of maximum 12), which altogether suggested the di-
agnosis of severe pancolitis (Mayo Endoscopic Score 
(MES) 3) (Fig. 1). Therefore, we started therapy with 
intravenous steroids (methylprednisolone 60 mg).
Due to a steroid-dependent disease, previously de-
scribed side effects to steroid therapy and inadequate 
response to azathioprine, we suggested biological ther-
apy (infliximab). The patient refused biological therapy, 
as well as colectomy, so we decided to start with LCAP 
as a treatment procedure. The patient was treated ac-
cording to the following scheme: initially twice a week 
for two weeks, then once a week for a month, and then, 
depending on the success of therapy, maintenance 
therapy once a month. During hospital stay, the pa-
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tient underwent three LCAP cycles. There was no side 
effects observed, while clinical and laboratory im-
provement was achieved. At discharge, the patient had 
3-4 stools per day without a tinge of mucus or blood. 
The value of Mayo Score was 4 (MES 1) (Fig. 2). Ane-
mia was corrected by transfusion of red blood cell 
(RBC) concentrate (a total of 2100 mL). After dis-
charge from the hospital, therapeutic LCAP was con-
tinued in an outpatient setting by the previously de-
scribed scheme. The patient’s condition remained sta-
ble, the number of stools was two to three formed 
stools daily, with no pathologic tinge. The patient was 
afebrile and had a body weight increase of 4 kg and 
MES around 2-3. The inflammatory parameters re-
mained within the reference intervals, while anemia 
was corrected by transfusion of RBC concentrate two 
times (per 570 mL). The patient underwent a total of 
12 therapeutic procedures during three months. 
Changes in the CRP levels during that period are 
shown in Figure 3, and changes in hemoglobin levels 
in Figure 4. In addition, therapy with mesalazine 4 g 
and azathioprine 2 mg/kg/day with nutritional sup-
port (polymeric enteral nutritional supplement 1.5 
kcal/mL, 1-2 packages per day) was continued. There 
was no need for steroid therapy. Refractory anemia was 
thought to be a side effect of azathioprine, therefore 
this drug was excluded from therapy. However, labora-
tory tests still indicated persistence of secondary ane-
mia and persistence of slightly elevated inflammatory 
parameters (CRP 24 mg/L). Two years after the end of 
LCAP, the patient’s clinical condition was stable while 
taking mesalazine, the patient had constant body 
weight and was afebrile with 2-3 formed stools daily 
with no pathologic tinge. Over the next six years, the 
patient refused regular disease monitoring or colonos-
copy and did not refer to our outpatient clinic. He was 
hospitalized again in 2015, but this time due to ap-
pendicitis with appendicular abscess. At this point, we 
found out that the patient had not been taking his 
medical therapy for several years, and had failed to 
Fig. 1. Rectosigmoidoscopy before leukocytapheresis – Mayo Score 3: edema, spontaneous 
bleeding, ulcerations, pseudopolyps.
Fig. 2. Rectosigmoidoscopy after leukocytapheresis – Mayo Score 1: erythema, decreased 
vascular pattern, mild friability, pseudopolyps.
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present for regular follow up examinations (last colo-
noscopy performed in 2007), despite occasionally 
 having clear symptoms and signs of disease activity. 
After refusing further medical treatment and endo-
scopic reevaluation, he was hospitalized again in 2017, 
but this time due to perforation of the colon. The pa-
tient underwent emergency surgery, which revealed 
transverse colon stenosis; therefore, subtotal colectomy 
was performed. Histopathologic analysis confirmed 
adenocarcinoma of the colon with positive malignant 
cells in local lymph nodes and lymphovascular inva-
sion (Dukes C, Modified Aster-Coller C2, TNM 
 classification pT3N2bMx). The tumor was a microsat-
ellite stable tumor. Positron-emission tomography-
computed tomography scan showed pathologic accu-
mulation in the liver and mediastinal and cervical 
lymph nodes. Due to metastatic carcinoma of the co-
lon, until now the patient received 10 cycles of a com-
bination of bevacizumab with FOLFIRI regimen, had 
laboratory findings in the reference range and was 
feeling well.
Discussion
Leukocytapheresis is a method that is used in many 
clinical conditions, mainly in autoimmune related dis-
orders, such as multiple sclerosis, dermatomyositis and 
rheumatoid arthritis8. There are two basic methods for 
extracorporeal removal of leukocytes, i.e. centrifugal 
and adsorptive methods. Adsorptive cytapheresis is a 
therapeutic procedure in which patient’s blood is 
passed through a medical device, which contains a 
 column or filter that selectively adsorbs activated 
monocytes and granulocytes. In centrifugal method, 
blood cells are separated based on their specific gravity, 
and both leukocytes and plasma that contains inflam-
matory cytokines are removed9. Adsorptive method 
has proved to be effective and includes granulocyte 
and monocyte/macrophage adsorptive apheresis 
(GMCAP) and LCAP. GMCAP removes about 65% 
granulocytes, 55% monocytes, and a very small num-
ber of lymphocytes, whereas LCAP removes about 
100% granulocytes and 61% lymphocytes6,10. LCAP 
also removes about 30% of activated platelets that can 
help the process of tissue repair11. Significant differ-
ence between the efficiency of LCAP and GMCAP 
has not been demonstrated12. According to current 
apheresis guidelines, selective apheresis is a potentially 
useful adjunct for the management of inflammatory 
bowel disease with the goal of removing activated leu-
kocytes or moderating their proinflammatory nature 
towards an immune modulatory phenotype13. Based 
on recent clinical studies, three basic mechanisms by 
which LCAP shows its therapeutic action have been 
established: (a) reduction of the number of activated 
lymphocytes and dendritic cells; (b) weakening the 
function of dendritic cells; and (c) reduction of the 
 levels of proinflammatory cytokines (TNF-α, IL-1b, 
IL-6, IL-8, IFN γ).
Many studies have been conducted to evaluate the 
safety and efficacy of cytapheresis in the induction of 
remission in patients with UC. However, in most of 
these studies, small numbers of patients were included. 
Furthermore, there is a lack of randomized controlled 
trials, which could evaluate the effect of LCAP in the 
management of UC. Data from uncontrolled studies 
showed a high response rate in corticosteroid-naive 
patients and remission rate of 50% in patients with 
steroid-dependent or steroid-refractory UC14-20. Stud-
ies have shown that LCAP not only improves clinical 
Fig. 3. C-reactive protein (CRP) levels (mg/L) during 
leukocytapheresis (LCAP) cycles.
Fig. 4. Hemoglobin levels (g/L) during leukocytapheresis 
(LCAP) cycles.
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symptoms but also is effective in the induction of mu-
cosal healing21. Data from most of the trials showed 
that adverse side effects were much less frequent in 
patients treated with LCAP than those treated with 
steroids. An open-label multicenter randomized con-
trol study and a double-blind, prospective, case-con-
trolled study with sham apheresis as placebo treatment 
demonstrated the safety and efficacy of LCAP for 
treating active UC10,22. A large-scale prospective, ob-
servational study by the Japanese group of authors 
showed LCAP to be a safe and effective therapeutic 
option for active UC. Clinical remission was achieved 
in 68.9% (429/623) of patients, while 62.5% (145/232) 
of patients had mucosal healing. Patients having un-
dergone intensive LCAP (≥4 LCAP sessions within 
the first 2 weeks) achieved clinical remission more rap-
idly and frequently than patients in the weekly group. 
In addition, 10.3% (87/847) of patients had mild ad-
verse events and severe adverse events were observed in 
only 5 (0.6%) patients23. Although there is evidence 
that LCAP is effective treatment for the induction of 
remission, it has not shown such a good effect when 
used as maintenance therapy24. However, a recent mul-
ticenter, retrospective, observational study of clinical 
outcomes and risk factors for UC relapse at 1 year af-
ter LCAP showed the 1-year cumulative relapse-free 
rate in the majority of patients (63.6%)25. In our se-
verely steroid-dependent patient with UC, we ob-
served fast response to therapy and improvement of 
general condition, clinical symptoms and signs, and 
laboratory parameters. There were no adverse effects, 
which is consistent with literature data on larger pa-
tient samples. In addition, our patient remained in 
clinical remission for two years, in which period he 
paid regular follow up visits to outpatient clinic. Inter-
estingly, over a 10-year follow up after LCAP, the pa-
tient had only occasional clinical symptoms of disease 
activity, without the need for hospital treatment. De-
velopment of metastatic carcinoma of the colon points 
to the importance of regular disease monitoring and 
endoscopic evaluation, which was not performed for 
approximately 10 years due to the patient’s noncom-
pliance rather than the increased risk of malignant dis-
ease after LCAP, which has not been described in the 
literature. Patients with UC are a demanding group of 
patients that warrant search for novel treatment strate-
gies other than conventional pharmacological thera-
pies. Although LCAP is still not a common treatment 
modality in our daily practice, data from recent studies 
suggest it to be an effective and safe procedure in the 
management of active UC patients. Larger studies are 
needed to show long-term beneficial effects of this 
therapy.
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Sažetak
LEUKOCITAFEREZA U LIJEČENJU TEŠKOG, O STEROIDIMA OVISNOG ULCEROZNOG KOLITISA
Ž. Krznarić, P. Markoš, B. Golubić Ćepulić, S. Čuković-Čavka, V. Domislović, I. Bojanić, A. Barišić i D. Kekez
Ulcerozni kolitis (UC) je kronična bolest multifaktorske etiologije čiji detaljan mehanizam imunološkog procesa još nije 
sasvim razjašnjen, ali ključnu ulogu svakako imaju granulociti i monociti/makrofazi koji reguliraju i pojačavaju upalni proces 
lučenjem proupalnih citokina. Leukocitofereza (LCAP) je terapijski postupak kojim se prolaskom krvi kroz sustav za aferezu 
odstranjuju limfociti i plazma prije nego što se krv ponovno vrati u krvotok. U ovom radu je prikazan o steroidima ovisan 
bolesnik s teškim relapsom UC-a koji je, prvi put u Hrvatskoj, liječen protokolom LCAP. Nakon 12 terapijskih protokola 
LCAP kod bolesnika je došlo do značajnog kliničkog poboljšanja bez razvoja nuspojava. Bolesnik je ostao u kliničkoj remi-
siji tijekom dvije godine ambulantnog praćenja, a unutar 10 godina praćenja nakon LCAP bolesnik je imao tek povremene 
simptome aktivnosti bolesti. Klinički tijek bio je kompliciran razvojem metastatskog karcinoma debelog crijeva, što prven-
stveno upućuje na važnost redovitog praćenja bolesti, a ne na povećan rizik maligne bolesti nakon LCAP. Bolesnici s UC-om 
su zahtjevna skupina pacijenata koja zahtijeva potragu za novim terapijskim strategijama osim onih konvencionalnih farma-
koloških. Iako LCAP nije čest modalitet liječenja u svakodnevnoj kliničkoj praksi, novije studije upućuju na to da je postupak 
učinkovit i siguran u liječenju bolesnika s aktivnim UC-om.
Ključne riječi: Leukafereza; Kolitis, ulcerozni; Kolorektalni tumori; Hrvatska; Prikazi slučaja
